EUVIMEDEUVIMED entdecken
Crossref

Evaluation of suppressor behavior of guanidine‐derived metformin and galegine as novel potential drugs for cancer treatment: an in silico study

Mohammad Behrouzi Varjovi iD, Rasool Asghari-Zakaria, Ghader Hosseinzadeh

Biotechnology and Applied Biochemistry · 2024

DOI: 10.1002/bab.2636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2024. Verfasst von Mohammad Behrouzi Varjovi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Agriculture, Department of Crop Production and Genetics, University of Mohaghegh Ardabili, Ardabil, Iran. Hauptthemen laut MEDLINE: Metformin, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are some natural products from plants that can prevent and treat disease. Metformin, a derivative of galegine, is the basic drug to treat diabetes. Moreover, this molecule has anticancer properties that inhibit cancer cell growth and proliferation. In this study, the main interactions of galegine and metformin with various cancer‐involved proteins, including mitochondrial alpha‐glycerophosphate dehydrogenase, yeast NADH dehydrogenase, and transforming growth factor‐β1, were surveyed by molecular docking and molecular dynamics simulations. The results showed that each of the proteins makes complexes with the ligands via favorable non‐bonded interactions, especially hydrogen bond interactions. There is greater stability for complexes containing galegine based on the root mean square deviation results. The higher structure compactness is also found in galegine receptors than in metformin receptors. Calculation of Δ G binding , using the MM/PBSA methodology, shows that the binding energy values for metformin and galegine in interaction with each of the receptors are almost the same, and galegine has similar binding properties with metformin in interaction with the studied protein receptors. Therefore, galegine, a natural ingredient with better binding properties to cancer‐involved proteins than metformin (with various side effects), can be applied as a new drug for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminNeoplasmsHumansAntineoplastic AgentsMolecular Docking SimulationGuanidineMolecular Dynamics SimulationGlycerolphosphate DehydrogenaseComputer Simulation

Stichwörter der Autor:innen

Ndi1TGF‐β1galeginemGPDmetforminmolecular dynamics simulation

Substanzen

MetforminAntineoplastic AgentsGuanidineGlycerolphosphate Dehydrogenase

Autor:innen und Institutionen

  • Faculty of Agriculture, Department of Crop Production and Genetics, University of Mohaghegh Ardabili, Ardabil, Iran.
  • Faculty of Engineering, Department of Chemical Engineering, University of Bonab, Bonab, Iran.

ORCID-Profile: Mohammad Behrouzi Varjovi

Zitieren

APA

Behrouzi Varjovi, M., Asghari-Zakaria, R., & Hosseinzadeh, G. (2024). Evaluation of suppressor behavior of guanidine‐derived metformin and galegine as novel potential drugs for cancer treatment: an in silico study. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2636

Vancouver

Behrouzi Varjovi M, Asghari-Zakaria R, Hosseinzadeh G. Evaluation of suppressor behavior of guanidine‐derived metformin and galegine as novel potential drugs for cancer treatment: an in silico study. Biotechnology and Applied Biochemistry. 2024. doi:10.1002/bab.2636

BibTeX
@article{BehrouziVarjovi2024,
  author = {Behrouzi Varjovi, Mohammad and Asghari-Zakaria, Rasool and Hosseinzadeh, Ghader},
  title = {Evaluation of suppressor behavior of guanidine‐derived metformin and galegine as novel potential drugs for cancer treatment: an in silico study},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2024},
  doi = {10.1002/bab.2636}
}
Kostenlos starten →